ATI’s Aeglea Announces Pricing of Initial Public Offering
AUSTIN, Texas– Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at an initial public offering price of $10.00 per share. The shares are expected to begin trading on The NASDAQ Global Market on April 7, 2016 under the symbol “AGLE.” In addition, Aeglea has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock.
UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities are acting as joint book-running managers for the offering. Needham & Company is acting as co-manager.
Aeglea was admitted to ATI in March 2014: http://www.prweb.com/releases/2014/03/prweb11694770.htm
About Aeglea BioTherapeutics
Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the engineered human enzymes are designed to degrade specific amino acids in the blood in order to reduce toxic levels of amino acids in inborn errors of metabolism or to exploit the dependence of certain cancers on specific amino acids. In addition to the ongoing Phase 1 clinical trial in solid tumors with its lead product candidate AEB1102, Aeglea expects to begin trials in 2016 of AEB1102 in patients with Arginase I deficiency and in cancer patients with hematological malignancies. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine.